$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
奥拉帕尼常见的不良反应
2025-10-19 11:44:20
Check Details
尼拉帕尼显著改善卵巢癌患者生存期
2025-10-19 11:44:20
Check Details
卡博替尼适应症之卵巢癌
2025-10-19 11:44:20
Check Details
多吉美抗肿瘤治疗之卵巢癌
2025-10-19 11:44:20
Check Details
奥拉帕尼获批的适应症
2025-10-19 11:44:20
Check Details
欧盟批准奥拉帕尼BRCA突变卵巢癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼复发性卵巢癌患者新希望
2025-10-19 11:44:20
Check Details
PARP抑制剂引发卵巢癌范式的最大转变
2025-10-19 11:44:20
Check Details
老年卵巢癌患者可以服用奥拉帕尼吗?
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗卵巢癌效果如何?
2025-10-19 11:44:20
Check Details
奥拉帕尼用于BRCA突变晚期卵巢癌一线治疗
2025-10-19 11:44:20
Check Details
尼拉帕尼延长了卵巢癌患者无进展生存期
2025-10-19 11:44:20
Check Details
1
2
...
6851
6852
6853
6854
6855
6856
6857
...
10242
10243
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sparsentan Drug Interactions: Hypotension, Hyperkalemia, Renal Risk, CYP3A
2
How to Take Vigabatrin: Dosing and Vision Monitoring
3
Who Makes Belzutifan: Welireg and Merck/ MSD Explained
4
FDA Approves Infilbray for GD3 Neurological Symptoms
5
How to Take Selinexor: Dosing, Food, and Safety
6
FDA Approves Nelkarmi for ALK-TKI-Resistant NSCLC
7
FDA Approves Lembaz: First Therapy Shown to Extend Survival in Infantile-Onset NPC
8
Klygefa FDA Approval: Weekly Subcutaneous C5 Inhibition for AChR-Positive gMG
9
What Is Pralsetinib? RET-Positive Lung and Thyroid Cancer Explained
10
Sotorasib Diarrhea in NSCLC: Grading, Loperamide and Dose Adjustment
11
Avatrombopag vs Eltrombopag in ITP: Onset, Dosing Rules and Pre‑Procedure Use
12
Gilteritinib and Differentiation Syndrome in AML: Recognition, Emergency Management and Monitoring